AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 5 Aug · 1 min read

Aurobindo Pharma Q1 FY27 revenue up 16.3%, led by Europe and Growth Markets

Aurobindo reported consolidated Q1 FY27 revenue of ₹9,150 crore and net profit of ₹1,032 crore, with growth across formulations and API.

What was filed

Aurobindo Pharma released a press release covering its unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The disclosure reports year-on-year growth in revenue, operating EBITDA and net profit, alongside a geography- and business-wise breakdown of sales. The company will host an earnings call at 8.30 AM IST on 6 August 2026.

Where the growth came from

Per the filing, revenue rose across all business lines. Europe was the fastest-growing large segment in rupee terms — an 11.0% rise in euro terms — and now accounts for 32.1% of consolidated revenue. Growth Markets formulations expanded the most in percentage terms. US revenue growth was more measured, which the company attributes to volume gains and new launches, partially offset by the absence of transient product sales. ARV revenue was broadly stable. On the API side, the company flagged sequential seasonal softness in its antibiotics portfolio even as year-on-year API revenue grew.

The company said it received final USFDA approval for 10 products during the quarter, several of them first-to-file, spanning anti-diabetic, antifibrotic and cardiovascular therapy areas. On a cumulative basis it reports 896 ANDA filings with 737 final approvals.

Balance sheet and cash

The filing states Aurobindo held a net cash position (including investments) of USD 42 million as on 30 June 2026, after paying USD 247 million for the Lannett acquisition and completing an USD 85 million buyback during the quarter. Free cash flow for the quarter was USD 98 million. Reported EBITDA excludes a one-time ₹43 crore impact from derecognition of a lease receivable, per the filing footnote.

Revenue from Operations (Q1 FY26): ₹7,868 Cr → ₹9,150 CrQ1 FY26 → Q1 FY27+16%^‡
Net Profit (Q1 FY26): ₹824 Cr → ₹1,032 CrQ1 FY26 → Q1 FY27+25%^‡
Operating EBITDA (Q1 FY26): ₹1,603 Cr → ₹1,924 CrQ1 FY26 → Q1 FY27+20%^‡
Net margin ‡: 10.5% → 11.3%Q1 FY26 → Q1 FY27held ~11%

US revenue (Q1 FY27): ₹3,770 Cr
Europe revenue (Q1 FY27): ₹2,937 Cr
Growth Markets revenue (Q1 FY27): ₹1,063 Cr
Basic & Diluted EPS: ₹17.86 per share
USFDA final approvals in quarter: 10 products
Net cash position as on 30-Jun-26: USD 42 million
Free cash flow in quarter: USD 98 million

‡ Computed by us from the filing’s own figures — not a company-stated number.

For a holder, this is the company's first quarterly report of FY27, setting out how each geography and business line performed and showing the cash position after the Lannett acquisition and a buyback. The figures are unaudited and reflect a single quarter.